These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25695044)

  • 21. New agents in follicular lymphoma.
    Cheson BD
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission of adult acute lymphocytic leukaemia with alemtuzumab.
    Laporte JP; Isnard F; Garderet L; Fouillard L; Gorin NC
    Leukemia; 2004 Sep; 18(9):1557-8. PubMed ID: 15229619
    [No Abstract]   [Full Text] [Related]  

  • 23. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
    Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Features of rituximab-induced killing of B lymphocytes.
    Youinou P; Mankaï A; Bordron A; Berthou C
    Scand J Immunol; 2008 Aug; 68(2):118-9. PubMed ID: 18702742
    [No Abstract]   [Full Text] [Related]  

  • 26. Selective loss of vaccine-specific memory B cells in a rhesus macaque model of chemotherapy: influence of doxorubicin on immunological memory.
    Ingelman-Sundberg HM; Saghafian-Hedengren S; Jahnmatz M; Eksborg S; Jonker M; Nilsson A
    Haematologica; 2015 Apr; 100(4):e158-61. PubMed ID: 25552706
    [No Abstract]   [Full Text] [Related]  

  • 27. CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL.
    Pittner BT; Jelinek DF; Kay NE
    Leukemia; 2004 Jan; 18(1):180-2. PubMed ID: 14523466
    [No Abstract]   [Full Text] [Related]  

  • 28. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.
    Abulayha AM; Tabal SA; Shawesh EI; Elbasir MA; Elbanani AS; Lamami YM; Bredan A
    Leuk Res; 2010 Mar; 34(3):307-11. PubMed ID: 19580998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of prednisone and cytostatics on human blood B-, T- and O-lymphocytes in diseases.
    Jonsson V
    Scand J Haematol; 1975 Sep; 15(2):109-16. PubMed ID: 1081272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prohibitin expression is increased in phorbol ester-treated chronic leukemic B-lymphocytes.
    Woodlock TJ; Bethlendy G; Segel GB
    Blood Cells Mol Dis; 2001; 27(1):27-34. PubMed ID: 11162143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Successful treatment by ranimustine (MCNU) of a patient with B-cell prolymphocytic leukemia (B-PLL)].
    Wake A; Yamasaki Y; Ogawa R; Mori N; Nagata K; Nakata K; Misago M; Izumi Y; Fujita K; Oda S
    Rinsho Ketsueki; 1993 Nov; 34(11):1464-9. PubMed ID: 8254909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.
    Anolik JH; Friedberg JW; Zheng B; Barnard J; Owen T; Cushing E; Kelly J; Milner EC; Fisher RI; Sanz I
    Clin Immunol; 2007 Feb; 122(2):139-45. PubMed ID: 17008130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation of purified malignant B cells induced by PMA or by activated normal T cells.
    van Kooten C; Rensink I; Aarden L; van Oers R
    Leukemia; 1993 Oct; 7(10):1576-84. PubMed ID: 8105156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppression in childhood acute lymphoblastic leukemia after remission induction therapy concerns B not T lymphocytes.
    Luczynski W; Krawczuk-Rybak M; Muszynska-Roslan K; Stasiak-Barmuta A; Zak J
    Med Pediatr Oncol; 2002 Aug; 39(2):147-8. PubMed ID: 12116070
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Travelstead AL; Longee D
    Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flipping the cyclin D1 switch in mantle cell lymphoma.
    Hasanali Z; Sharma K; Epner E
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of ethylenebisnitrosourea on the functions of murine lymphocytes].
    Teshima R; Sawada J; Ikebuchi H; Terao T
    Eisei Shikenjo Hokoku; 1983; (101):19-22. PubMed ID: 6609734
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimal residual disease and survival in chronic lymphocytic leukemia.
    Hillmen P
    Clin Adv Hematol Oncol; 2005 Jul; 3(7):522-4. PubMed ID: 16167030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.